Human and mouse macrophages release a fibrinolytic inhibitor after stimulation by endotoxin in vitro. The released mouse inhibitor was indistinguishable in size by molecular-sieve chromatography from an intracellular form (approx. 50kDa), and both inhibitors blocked urokinase directly as judged by a 125I-plasminogen conversion assay. The intracellular inhibitor was found mostly to dissociate from 1251-urokinase during sodium dodecyl sulphate/polyacrylamide-gel electrophoresis under reduced conditions, but a dodecyl sulphate-stable complex at 65-67 kDa was observed. Because of similarities in the reported size, stability and urokinase-binding properties of a placental urokinase inhibitor, the kinetic properties of the two inhibitors were compared. Under the reaction conditions employed (37°C at pH 7.4 in the presence of 0.2% Triton X-100), the association rate constants and equilibrium dissociation constants of the two inhibitors were indistinguishable, 3 x 105M-1 S-1 and 4 x 10-10M respectively. These data show that peritoneal macrophages contain a plasminogen-activator very similar to a previously recognized placental inhibitor.
Stimulated mouse and human macrophages at extravascular sites of inflammation regulate the deposition and turnover of fibrin/fibronectin by at least three mechanisms. First, the cells secrete fibronectin and synthesize and express on their cell surface the initial enzyme complex of the extrinsic pathway of coagulation (Rennard et al., 1981; Chapman et al., 1985) . Secondly, the cells express a membrane-bound form of a urokinase-type plasminogen activator (PA) and secrete a similar enzyme in soluble form (Chapman et al., 1984; Lemaire et al., 1983) . Thirdly, the cells, on stimulation with endotoxin, accumulate intracellularly and release extracellularly a fibrinolytic inhibitor of urokinase-type PA (Chapman et al., 1982) . The expression of these several factors by macrophages seems to be co-ordinately regulated to favour either fibrin/fibronectin accumulation or resorption. The fibrin/fibronectin in tissues may in turn influence the mobility and distribution of macrophages and the course of healing (Leibovich & Ross, 1975; Repesh et al., 1982; Hedelin et al., 1983; Chapman et al., 1983) . Several lines of evidence suggest that fibrin/fibronectin in tissues may serve as a provi sional matrix for fibroblast proliferation and subsequent scar formation (Kwaan & Astrup, 1969; Kurkinen et al., 1980; Grinnell et al., 1980; Bitterman et al., 1983; Holund et al., 1984) .
The nature of the fibrinolytic inhibitor expressed by endotoxin-stimulated macrophages is unclear. Recent (Kwano et al., 1970) . The kinetics of binding of the placental inhibitor with urokinase have been reported (Christensen et al., 1982) . Insufficient human macrophage PA inhibitor is available for a similar analysis. In the present study we have examined the functional properties of a partially purified preparation of PA inhibitor from endotoxin-stimulated mouse peritoneal macrophages. In particular, we have examined the physical nature and kinetics of interaction of the macrophage inhibitor with urokinase and compared the results with the properties of a placental inhibitor preparation examined under identical conditions.
Experimental

Reagents
Animal and human sera were prepared and stored as previously described (Chapman et al., 1982) . Human (Kaplan & Nielsen, 1979) . The unbound 125I was removed by molecular-sieve chromatography (Sephadex G-10) in the presence of bovine serum albumin carrier (1 mg/ml), and the labelled urokinase or plasminogen was divided into small portions and stored at -70°C. Human fibrinogen was obtained from Merck (West Point, PA, U.S.A.) and made plasminogen-free by repeated ethanol precipitation in the presence of lysine (Mosesson, 1962) . 125I-fibrinogen was obtained from Amersham (Chicago, IL, U.S.A.). A partially purified preparation of human placental urokinase inhibitor was obtained from a-Therapeutics (Los Angeles, CA, U.S.A.). Sodium dodecyl sulphate was obtained from Gallard-Schlesinger (New York, NY, U.S.A.). Endotoxin, a Westphal preparation of Salmonella enteritidis (Sigma Chemical Co., St. Louis, MO, U.S.A.), was used without further purification. Benzyloxycarbonyl-glycyl-glycyl-arginine 4-aminomethylcoumarinamide (Cbz-Gly-Gly-Arg-Amc; Enzyme Systems Products, Livermore, CA, U.S.A.), a previously studied substrate for urokinase, was used for fluorimetric assays of urokinase (Zimmerman et al., 1978; Chapman et al., 1982 (Chapman et al., 1982) . Briefly, the cell-free supernatants or lysates (100 p1) were assayed for inhibitor by mixing with 100l 1 of urokinase (0.5 unit) followed by incubation in 125I-fibrin-coated wells with plasminogen (8pg/ml) for 4h at 37°C. Degraded fibrin was assayed by fl-scintillation counting. Inhibitor activity is expressed as percentage inhibition of urokinase activity in control wells containing unconditioned media and represents a mean of triplicate determinations. The assays were generally done concurrently with I 251-plasminogen conversion assays, described below. The kinetic analysis of the interaction of the PA inhibitor with urokinase was done by fluorimetry basically as described by Christensen and coworkers but with some modifications (Christensen et al., 1982) . The interaction of the inhibitor with urokinase was studied at 37°C in phosphate-buffered saline containing 0.2% Triton X-100. The Triton was included because the partially purified inhibitor preparation contained small amounts of Triton and this critically influenced the reaction velocity. Triton, as reported by other investigators, appreciably increased the reaction rates (Unkeless et al., 1974) . By performing all assays in 0.2% Triton, this variable could be eliminated. The molarity of the urokinase preparation was first determined by five separate active-site titrations withp-nitrophenyl guanidinobenzoate. The urokinase preparation was found to contain 0.12pmol/ unit. Small portions were stored at -70°C at 250 units/ml. The basic reaction conditions for subsequent experiments were urokinase (5.6-11.2 nM) and various amounts (2-30 p1) of inhibitor (1.36mg/ml) in a total volume of 500 Ml of phosphate-buffered saline containing 0.2% Triton X-100. After various times of incubation at 37°C, the urokinase substrate Cbz-Gly-Gly-Arg-Amc was added in 10 p1 to a final concentration of 0.1 mm, and the initial reaction rate was determined at 37°C in a Perkin-Elmer spectrofluorimeter interfaced with an X-Y recorder. The instrument settings were as previously described (Chapman et al., 1982) . In some experiments the substrate concentration was increased to 1.OmM final concentration. Preliminary data showed that no enzyme activity towards the urokinase substrate was measurable in the PA inhibitor preparation. However, it should be noted that the experiments cannot be done with crude lysates of the cells because the lysates contain PA as well as the inhibitor. We have reported the macrophage membrane' PA to be relatively resistant to the PA inhibitor (Chapman et al., 1982) . Presumably much or most of the inhibitor is membrane-bound in the lysate and fractionates at a different molecular mass from that of the inhibitor during chromatography because the inhibitor-rich fraction is devoid of PA activity.
The molarity of the PA inhibitor in the preparations tested was determined by titration of urokinase with various microlitre amounts of inhibitor. The enzyme and inhibitor were allowed to interact at 370C for 60min before analysis. The fractional urokinase activity (E/EO) was observed to decline in linear fashion with increasing microlitre amounts of inhibitor until E/Eo was not more than 0.35. Under these conditions, if the enzyme concentration is known, the inhibitor concentration can be calculated from the slope of the line (Christensen et al., 1982) . By this technique, the three preparations used for analysis in this study, at total protein concentrations of 1.4mg/ml, were 170nM, 112nM and 145nM in PA inhibitor.
In experiments with the placental inhibitor instead of the macrophage inhibitor, the freezedried placental inhibitor was also reconstituted in 0.2% Triton X-100/phosphate-buffered saline and the molarity determined by titration of urokinase as described above.
Autoradiography
We examined the fibrinolytic inhibitors by two autoradiographic techniques. Purified human plasminogen was iodinated and the inhibitor tested for its capability to block conversion of 1 251-plasminogen into 125I-plasmin. The assay was performed as described by Loskutoff & Edgington (1981) . Briefly, 5pl of 125I-plasminogen, 1.25 units of urokinase (5 p1 
Results
We have previously reported partial purification of an endotoxin-inducible PA inhibitor from mouse peritoneal macrophages. Molecular-sieve chromatography of the cellular lysate yields a single peak of inhibitory activity of approx. 45-50 kDa. This peak has a specific activity some 50-80-fold higher than that of the cell lysate (Chapman et al., 1982 and mechanism of action, we focused further studies on only one form of the inhibitor, the intracellular PA inhibitor. We did this because the cellular lysates consistently had greater inhibitory activity than did the supernatants. Moreover, in the absence of small amounts of serum (1%) in the culture medium, the PA inhibitor accumulated within the cells and much less activity was in the medium (results not shown). The presence of serum, however, interfered with the enzyme assays used. Therefore the studies described below utilized either cellular lysates or a partially purified fraction of the lysates.
Interaction of 125I-urokinase with macrophage PA inhibitor The autoradiograph shown in Fig. 2 illustrates the interaction of the macrophage PA inhibitor with 1 251-urokinase after electrophoresis in sodium dodecyl sulphate/polyacrylamide gels under reduced conditions. Lane 1 shows the 1251-urokinase alone. Lane 2 shows a discrete band at approx. inhibitor for 60min at 37°C. In multiple other experiments done in both 10% and 7.5% polyacrylamide gels, the complex migrated with apparent molecular mass of 65-67 kDa. We also determined the time course of formation of the complex between 1 251-urokinase and the inhibitor by terminating the incubation at various times from 5 min to 3 h at 37°C. A faint band was visible after 5min, and this progressively intensified during incubation up to 1 h. After 1 h at 37°C, no further change from that shown in lane 2 occurred. We also observed that heating the inhibitor preparation at 56°C for 30min before incubation with urokinase destroyed all binding (lane 3). All functional activity is lost by heating as well. Similarly, preincubation of 125I-urokinase with p-nitrophenyl guanidinobenzoate (1 mM), which blocks the active site, also totally blocked binding to the PA inhibitor (results not shown).
In addition to the discrete complex at 65-67kDa, there is a broad band of labelled enzyme above the normal migration of the 125I-urokinase heavy chain (33kDa). This broad band was also obliterated by either heating the inhibitor (lane 3) or inactivating the urokinase active site with pnitrophenyl guanidinobenzoate (results not shown). The autoradiograph in Fig. 2 also shows the interaction of a partially purified preparation of placental inhibitor (lanes 4, 5 and 6). The binding pattern of the placental inhibitor with urokinase appears similar to that of the macrophage inhibitor except that two less dense but discrete bands at 65-67kDa and 6OkDa are visible. Increasing the amount of placental inhibitor from 10 to 20 units (lanes 4 and 5) did not change the pattern of interaction. Again, heating the placental inhibitor at 56°C for 30 min (lane 6) or inactivation of urokinase with p-nitrophenyl guanidinobenzoate blocked all binding.
Fluorimetric assay of the inhibition of urokinase by the macrophage PA inhibitor
The ability of various amounts of the partially purified macrophage PA inhibitor to block urokinase amidolytic activity directly was studied. The inhibitor and enzyme were incubated at 37°C for 60min, the substrate was then added and the initial reaction rate was measured fluorimetrically. Enzymic activity in Fig. 3(a) is expressed as a ratio of the enzyme activity in the presence of inhibitor to that without inhibitor (E/EO). The data show that (Travis & Salvesen, 1983) . The data in Fig. 3(a) also show that, for fractional inhibition of 0.35 or more, there is a linear decline in urokinase activity with increasing microlitre amounts of inhibitor. Under this condition, the straight line shown in the Figure is defined by the equation: E/EO = -(I/Eo)Io+I where -l/EO is the slope of the line and IO is the concentration of inhibitor added to the reaction. Using this relationship and a known amount of urokinase (5.8 nM) in the reaction, we have calculated the nanomolar concentration of inhibitor in the partially purified preparations. The concentrations in three such preparations were 170nM (preparation used in Fig. 3a) , 112nM (preparation used in Fig. 3b ) and 145nm. This represents an average of 142pmol of PA inhibitor recovered from 240 x 106 macrophages. Data in Fig. 3(b) show that the prediction that the slope of the line should be proportional to enzyme concentration (EO) can be verified experimentally.
In the experiment, either 5.6nm-or 11.2nM-urokinase was mixed with various amounts of inhibitor and the initial reaction rate (after 60min at 37°C) was determined in the presence of 0.1 mM substrate. As judged by the x-axis intercept, a 2-fold increase in nanomolar enzyme concentration resulted in an approximately 2-fold increase in the inhibitor concentration necessary to neutralize the enzyme.
Calculation of kinetic constants for interaction of macrophage and placental PA inhibitors with urokinase Because the physical binding of the macrophage and placental PA inhibitors to urokinase appears to be quite similar (Fig. 2) , we next determined whether the kinetic constants of the two inhibitors were also similar. The association rate constant (ko0) and equilibrium dissociation constant (Kj) for the binding of human placental inhibitor and urokinase have been previously reported (Christensen et al., 1982) . We had to modify significantly the reaction conditions given in the previous report because the macrophage preparations contained small amounts of Triton X-100. This markedly influences the reaction rate of urokinase with substrate. By techniques identical with those described in Fig. 3 legend, we determined the nanomolar concentration of inhibitor in the human placental preparations. We then determined the time course of inhibition of 5.8 nM-urokinase by equimolar concentrations of macrophage or placental inhibitor at 37°C at pH 7.4 in the presence of 0.2% Triton X-100. Results are shown in Fig. 4 .
For each set of data (E/EO, t) a value for k0n was calculated (Christensen et al., 1982) . The mean kon for the macrophage PA inhibitor was 3 x 105 + 2 x 105M-1 *s-1. This value (±l S.D.) represents an average for ten data points and two Fig. 4 , the calculated k0n for the placental preparations was not significantly different, 2.8 x 105 + 1.2 x 105M-1 s-1. Calculated dissociation constants after 1 h incubation at 37°C at equivalent molar amounts of enzyme and inhibitor were 4 x 10-10 M for both inhibitor preparations.
Discussion
We have previously reported that mouse peritoneal macrophages express an endotoxin-inducible plasminogen-activator inhibitor. In the present study we have extended these observations in several respects. First, the 125I-urokinase binding data indicate that the inhibitor binds to the heavy chain of urokinase. This chain contains the active site; p-nitrophenyl guanidinobenzoate blocked the active site and blocked binding. The observed 65-67 kDa complex is smaller than the expected complex of 78-83 kDa (33 kDa heavy chain and 45-5OkDa inhibitor), and this suggests that a fragment of the inhibitor is removed during the interaction with urokinase. Cleavage of an inhibitor by a proteinase during their interaction with subsequent formation of a dodecyl sulphate-stable bond is common among inhibitors of serine proteinases (Travis & Salvesen, 1983) . We consider that the broad band above the normal migration position of urokinase in Fig. 2 represents urokinase dissociated from the inhibitor during electrophoresis, for the following reasons. The appearance of the band is blocked by inactivation of either the inhibitor (lane 3) or the enzyme (by p-nitrophenyl guanidinobenzoate) before electrophoresis. Also, Golder & Stephens (1983) have identified a urokinase inhibitor in cultured human monocytes. They assayed urokinase activity in gel slices after electrophoresis of mixtures of the monocyte inhibitor and urokinase. They observed a broad band of urokinase activity extending above the normal migration position of uncomplexed urokinase. This would be expected (and compatible with our data in Fig. 2 ) if enzyme-inhibitor complexes dissociated during the electrophoresis. They did not observe activity at 65-67 kDa, which would also be expected if this represents urokinase complexed with the inhibitor.
Secondly, the kinetic data (Fig. 4) indicate that the inhibitor is fast-acting and progressive in nature. These data also show that the inhibitor resembles the previously characterized human placental inhibitor but not known human serum inhibitors of urokinase. Christensen et al. (1982) reported a second-order rate constant for the placental inhibitor of 3.5 x 106 M-1 -S-. Our data show an association constant for this inhibitor of approximately an order of magnitude lower. The reason for this discrepancy is unclear, but it is probably because of the effect of Triton on the binding characteristics of enzyme, substrate and inhibitor. The addition of 0.2% Triton to the reaction mixture of urokinase and the fluorogenic substrate causes a several-fold increase in the initial reaction velocity (H. A. Chapman, unpublished work) . In any case, we could measure no difference in the rate constant between macrophage and placental PA inhibitors (Fig. 4) when both were assayed under identical conditions. In contrast, Waller et al. (1983) reported a secondorder rate constant of inhibition of urokinase by heparinized human serum of 93 M-I * S-l. This proved to be due largely to antithrombin III. This value is nearly 104-fold lower than that of either inhibitor studied in the present work. This result indicates the macrophage PA inhibitor is probably not a component of normal human serum. This conclusion is supported by the absence of a dodecyl sulphate-stable complex between urokinase and any serum inhibitor in the 65-72 kDa region in the absence of added heparin (Waller et al., 1983) .
Previous reports indicate a number of cellderived macromolecular proteins capable of directly inhibiting urokinase activity. To our knowledge, none of these inhibitors has been purified to homogeneity. Instead, the inhibitors have been chemically characterized by their ability to form dodecyl sulphate-stable complexes during incubation with 125I-urokinase. Baker et al. (1980) reported a 72kDa complex identified by electrophoresis under reducing conditions of a fibroblastderived urokinase inhibitor. This inhibitor also interacted strongly with thrombin. Vassalli et al. (1984) reported a human monocyte-derived inhibitor, without thrombin-binding properties, that formed a 72 kDa complex with low-molecularmass 125I-urokinase (33 kDa) under non-reducing conditions. Our observations indicate 60-67kDa complexes between 1 2I-urokinase and the macrophage and placental inhibitors. A comparison of the mouse macrophage and human placental inhibitor binding to urokinase (Fig. 2) (Christensen et al., 1982) .
It is notable that all of these inhibitors are of similar apparent size, 40-50kDa. These inhibitors may thus represent a group of genetically related Vol. 230 115 proteins that regulate extracellular PA activity. However, this hypothesis remains to be proven.
The similarities between the macrophage and placental tissue PA inhibitors raise the possibility that placental macrophages are the source of this tissue inhibitor. This is made plausible by the findings that macrophages account for at least 35% of the total cells recoverable from human placenta (Wilson et al., 1983) . Interestingly, the macrophage PA inhibitor is not a constitutive cellular protein, but instead is expressed in response to activating stimuli. For example, human alveolar macrophages lavaged from normal lungs do not contain the PA inhibitor. However, these cells express and secrete the inhibitor after stimulation by endotoxin in vitro (H. A. Chapman & 0. L. Stone, unpublished work). Further study is needed to determine directly whether human placental macrophages produce the PA inhibitor and whether the expression of the inhibitor is subject to regulation by relevant signals, e.g. hormones.
